Anti-Leukotriene Therapy may be Effective for the Treatment of Salivary Eosinophilic Inflammation  by Shirasaki, Hideaki et al.
Allergology International Vol 61, No1, 2012 www.jsaweb.jp 175
Fig.　1　Time course of clinical symptoms and the levels of eosinophils (%) in peripheral blood. Each ar-
row indicated the episode of cheeck swelling.
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Dear Editor
Anti-Leukotriene Therapy may be
Effective for the Treatment of
Salivary Eosinophilic Inflammation
Fibrinous sialodochitis is a very rare disease, and its
most common symtoms include swelling of paroitid
gland and excretion of sticky mucous plugs contain-
ing numerous eosinophils from Stensen’s duct. Fibri-
nous sialodochitis has been believed to involve aller-
gic response in the salivary duct and parotid glands.
Unfortunately, the effective medical treatment except
for the administration of glucocorticoid was not
known. We experienced a case of fibrinous sialodo-
chitis who was successfully treated with montelukast
as follows:
On January 7, 2007, a 51-year-old woman presented
to our hospital with a 3-year history of recurring bilat-
eral parotid gland swelling and parotid pain during
and after meals over 6 to 48 hours at least once per
week. Previously, she visited two other ENT clinics
for these symptoms. On questioning, the previous
medication with antihistamines had no effect on these
symptoms, while oral administration of prednisolone
(10-20 mgday) for one or two days palliated her pa-
rotid symptoms. She came to our hospital, expecting
to receive the effective medication other than sys-
temic steroids. She also complained of allergic rhini-
tis. Physical examination showed the nasal mucous
membrane to be pale and edematous, the turbinates
hypertrophied. An intraoral examination showed nei-
ther dryness nor atrophy of the oral mucous mem-
brane. The blood examination except for the percent-
age of peripheral eosinophils (10.4%) and total IgE
(295 kUL) was within normal limits. Specific IgE lev-
els of major inhaled allergens were also within nor-
mal limits. Examination for autoantibodies, such as
the antinuclear antibody, SS-A and SS-B antibody,
were all negative.Hansel staining showed that the
mucous plugs from her Stensen’s duct contained nu-
merous eosinophils. Nasal smears also showed
marked eosinophilia. A diagnosis of fibrinous sialodo-
chitis complicated nonallergic rhinitis with eosino-
philia syndrome was made. We started to the treat-
ment of disease with an anti-allergic agent, suplatast
tosilate (300 mgday). However, this medicine was
without any effect for her parotid symptoms. Then,
medication was changed to an anti-leukotriene ther-
apy with montelukast (10 mgday). She recognized
the initial objective improvement from two weeks af-
ter the start of the treatment. The frequency of
cheeck swelling began to be lessened, and peripheral
eosinophil levels were gradually decreased (Fig. 1).
In adittion, there has been no exacerbation of her na-
sal symptoms. Athough we have proposed to reduce
the dose of montelukast, she hopes to continue the
medication with the same doses. To date these has
been no adverse effects in this case.
Because the present case also complained of aller-
gic rhinitis, we tried to use the cysteinyl leukotriene
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antagonist in spite of no previous report concerning
the efficacy of cysteinyl leukotriene antagonists on fi-
brinous sialodochitis. In vitro, it has beeen reported
that LTD4 extended the survival of eosinophils and
CysLT1 receptor antagonist caused the apoptosis of
eosinophils. 1 In previous clinical radomized trial,
daily treatment with montelukast for 4 weeks re-
duced sputum and blood eosinophils and improved
clinical asthma control with placebo.2 So, CysLT1 re-
ceptor antagonists have been thought to have the
benefits for eosinophilic inflammation. The clinical ef-
ficacy of montlelukast on the present case suggests
that cysteinyl leukotrienes may play some important
roles on fibrinous sialodochitis. Recently, higher con-
centrations of cysteinyl leukotrienes in saliva from
asthmatic patients has been reported. 3 In order to
confirm the roles of cysteinyl leukotrienes on fibri-
nous sialodochitis, the quantitative measurement of
salivary cyslteinyl leukotrienes will be needed.
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